RAPT Therapeutics (FRA:0RA) 3-Year EBITDA Growth Rate : -15.00% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is RAPT Therapeutics 3-Year EBITDA Growth Rate?

RAPT Therapeutics's EBITDA per Share for the three months ended in Mar. 2024 was €-0.77.

During the past 3 years, the average EBITDA Per Share Growth Rate was -15.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 4.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of RAPT Therapeutics was 35.60% per year. The lowest was -15.00% per year. And the median was -5.10% per year.

Competitive Comparison of RAPT Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, RAPT Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RAPT Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RAPT Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where RAPT Therapeutics's 3-Year EBITDA Growth Rate falls into.

RAPT Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

RAPT Therapeutics (FRA:0RA) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

RAPT Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of RAPT Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

RAPT Therapeutics (FRA:0RA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RAPT Therapeutics Inc (FRA:0RA) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

RAPT:USA

Address

561 Eccles Avenue, South San Francisco, CA, USA, 94080

Website

https://www.rapt.com

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

RAPT Therapeutics (FRA:0RA) Headlines

No Headlines